Estimated Cost of Adverse Event Management in Treatment Naïve Non-small Cell Lung Cancer Patients with Common EGFR Mutations Treated with Amivantamab Plus Lazertinib and Osimertinib Plus Chemotherapy (Journal of Health Economics and Outcomes Research, 2026)